National Council for Prescription Drug Programs indexing - billing unit

Manufacturer: National Council for Prescription Drug Programs
Effective date: 2012-07-24
Label type: Indexing - Billing Unit
Version: 1
Source: full-release
Hydrated at: 2026-06-05 01:12:25

Label at a glance#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
55566-8505-2	EA - Each	55566-8505	141be804-2199-4676-b722-2c506c7dba08	1	2012-07-24

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
55566-8505	55566-8505-2

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog.

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2019-12-13 00:20 UTC	2019-12	N021289-001	BRAVELLE	75 IU/VIAL	INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS	RLD	2002-05-06	`74a2ff9319b5…`
2019-12-14 00:12 UTC	2019-12	N021289-001	BRAVELLE	75 IU/VIAL	INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS	RLD	2002-05-06	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N021289-001	BRAVELLE	75 IU/VIAL	INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS	RLD	2002-05-06	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N021289-001	BRAVELLE	75 IU/VIAL	INJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS	RLD	2002-05-06	`ea99ee380514…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.